# PRP and stem cells

Rating: Promising — Some human trials, or consistent animal work with a clear mechanism
Type: Therapy
Updated: 2026-10-15
Canonical: https://heretic.bio/articles/prp-and-stem-cell-therapies.html

> PRP concentrates your own platelets to deliver growth factors to damaged tissue; stem cell therapy delivers progenitor cells that work mainly through paracrine signaling. PRP has real trial support: multiple randomized trials show it beating hyaluronic acid and saline in knee osteoarthritis, plus positive data in tendinopathy and hair loss, with an excellent safety profile as an autologous product. Stem cell evidence is weaker and most orthopedic stem cell treatments are not FDA-approved, with unregulated clinics a real hazard.

> **Core thesis:** Platelet-rich plasma (PRP) and stem cell therapies represent the biological frontier of regenerative medicine. By concentrating the body's own healing factors (PRP) or delivering progenitor cells (stem cells) directly to damaged tissue, these approaches can promote genuine tissue repair rather than merely managing symptoms.

* * *

## Platelet-Rich Plasma (PRP)

### What Is PRP?

  * Autologous (from your own body) concentrate of platelets in a small volume of plasma
  * Platelets contain **alpha granules** packed with growth factors:
  * **PDGF** (platelet-derived growth factor) — cell proliferation, angiogenesis
  * **TGF-β** (transforming growth factor beta) — collagen production, tissue remodeling
  * **VEGF** (vascular endothelial growth factor) — new blood vessel formation
  * **EGF** (epidermal growth factor) — tissue regeneration
  * **FGF** (fibroblast growth factor) — fibroblast activation, wound healing
  * **IGF-1** (insulin-like growth factor) — cell growth, tissue repair
  * Typical concentration: 3-8x baseline platelet count



### PRP Preparation

  1. **Blood draw:** 20-60 mL of venous blood
  2. **Centrifugation:** Single or double spin to separate platelet-rich layer
  3. **Activation:** Calcium chloride or thrombin (optional) to trigger growth factor release
  4. **Injection:** Under ultrasound guidance into target tissue



### Types of PRP

Type | Characteristic | Best For  
---|---|---  
**Leukocyte-rich PRP (LR-PRP)** | Contains white blood cells | Tendinopathy, chronic inflammation  
**Leukocyte-poor PRP (LP-PRP)** | Minimal white blood cells | Osteoarthritis, intra-articular use  
**Platelet-poor plasma (PPP)** | Low platelets, high fibrin | Used as scaffold in some protocols  
  
### Clinical Evidence

#### Osteoarthritis (Moderate-Strong)

  * Multiple RCTs show PRP superior to hyaluronic acid and saline for knee OA
  * Improvements in pain, function, and quality of life sustained 6-12 months
  * PMID: [PMC12604588](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12604588/) (2025) — "PRP therapy has emerged as a promising regenerative approach"
  * May slow cartilage degeneration (disease-modifying, not just symptom relief)



#### Tendinopathy (Moderate-Strong)

  * **Achilles tendinopathy:** PRP + eccentric exercise superior to exercise alone
  * **Lateral epicondylitis:** Multiple positive RCTs
  * **Patellar tendinopathy:** Growing evidence
  * **Rotator cuff:** Evidence mixed; surgical repair augmented with PRP shows benefit



#### Hair Loss (Androgenic Alopecia) (Moderate)

  * PRP injections into scalp promote hair follicle reactivation
  * Multiple RCTs show increased hair count and thickness
  * Maintenance sessions required every 3-6 months



#### Skin Rejuvenation ("Vampire Facial")

  * PRP + microneedling → collagen stimulation
  * Moderate evidence for skin quality improvement



* * *

## Stem Cell Therapies

### What Are Stem Cells?

  * **Undifferentiated cells** capable of self-renewal and differentiation into specialized cell types
  * **Paracrine effects:** Stem cells secrete cytokines, growth factors, and exosomes that modulate the local environment and recruit endogenous repair cells
  * **Immunomodulatory:** MSCs can modulate immune responses, reduce inflammation



### Types of Stem Cells

Type | Source | Characteristics | Regulatory Status  
---|---|---|---  
**MSCs (mesenchymal stromal cells)** | Bone marrow, adipose tissue, umbilical cord | Most studied for orthopedic use; differentiate into bone, cartilage, fat | Varies — largely research/off-label  
**Hematopoietic stem cells** | Bone marrow, peripheral blood | Blood cell formation; established for blood disorders | FDA-approved for specific conditions  
**Adipose-derived MSCs** | Fat tissue (liposuction) | Abundant, easy to harvest | Research/off-label  
**Umbilical cord-derived** | Birth tissue | Young cells, high proliferative capacity | Contested — FDA regulatory action  
  
### Mechanism of Action

  1. **Homing:** Stem cells migrate to injury/damage sites
  2. **Paracrine signaling:** Secrete trophic factors that modulate local environment
  3. **Anti-inflammatory:** Reduce pro-inflammatory cytokines, increase anti-inflammatory
  4. **Angiogenesis:** Promote new blood vessel formation
  5. **Differentiation:** Can directly become tissue cells (bone, cartilage, etc.)
  6. **Immunomodulation:** Modulate T-cell responses, reduce autoimmune activity



### Clinical Evidence

#### Osteoarthritis (Moderate)

  * Intra-articular MSC injection shows pain relief and functional improvement
  * Some imaging evidence of cartilage regeneration (contested)
  * PMID: [PMC11575995](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11575995/) — growing interest in combining PRP with stem cells
  * Durable benefits reported at 1-2 year follow-up in some studies



#### Intervertebral Disc Disease (Emerging)

  * Intradiscal MSC injection shows promise for disc regeneration
  * Pain reduction and improved function in pilot studies
  * Potential to avoid spinal surgery in selected patients



#### Tendon and Ligament Repair (Emerging)

  * MSC injection into tendon defects shows improved healing in animal models
  * Human evidence is preliminary but promising
  * Often combined with PRP or scaffolds



#### Other Applications

  * **Cardiac repair:** Post-MI cardiac regeneration (research stage)
  * **Neurological:** Stroke, spinal cord injury, MS (early research)
  * **Autoimmune:** Immunomodulatory effects being explored for lupus, RA, Crohn's



* * *

## Safety and Regulation

### PRP Safety

  * **Excellent safety profile** — autologous product, minimal risk
  * **Adverse events:** Mostly injection-related (pain, bruising, rare infection)
  * **No allergic risk** (your own blood)



### Stem Cell Safety

  * **Autologous MSCs** (from your own body): Generally safe, minimal rejection risk
  * **Allogeneic cells** (donor): Higher regulatory concern, potential immune reaction
  * **Serious adverse events:** Rare but reported (especially with unregulated clinics)



### The Regulatory Problem

  * **FDA has not approved** most stem cell therapies for orthopedic use
  * Many clinics operate under "same-day surgical exemption" or use research protocols
  * **Unregulated clinics** may use non-viable cell products or make exaggerated claims
  * **The field is legitimate but the industry has grifters** — vet clinics carefully



* * *

## Sources

1. Nguyen RT et al. (2024). "Biological Mechanisms of PRP." PMC12604588 (PMC12604588)
2. Fitzpatrick J et al. (2024). "PRP: A Bibliometric Analysis." PMC11575995 (PMC11575995)